Micromedic Technologies publishes triumphant Clinical Study results for detecting prostate cancer cells
Micromedic Technologies declared successful results of a Clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology. The study ascertained cells originated from the prostate in urine samples. Micromed’s product is designed to permit a simple and non-invasive method for direct and succinct discerning of malignant prostate cancer cells in urine samples.
The study included 59 urine samples (28 positive prostate cancer patients and 31 healthy subjects) that were collected and examined by a cytopathologist using the CellDetect® unique color marker. Of the 59 samples tested, a high rate of 80% of the samples received a definite diagnosis, and accordingly, included in the clinical study results. The results of the positive prostate cancer patients were compared to biopsy results that these patients had undergone prior to the clinical study.
Guy Lerner, Micromedic’s CEO stated “While prostate cancer is the second most common cancer in men worldwide, the currently available diagnostic testing is known to be unreliable. With these clinical study results, we are confident that our product has the potential to transform prostate cancer diagnostics, offering patients a non-invasive, accurate and reliable test, and one that could improve the healthcare system through considerable cost savings.”
The successful study results are considered breakthrough in the development and commercialization of Micromedic’s product as a simple and accurate diagnostic test compared to the current used tests. To the best of the Company’s knowledge, the accuracy and effectiveness of current used tests are questionable, mainly due to a high rate of false positive results (as low as 25% specificity), resulting in unnecessary invasive diagnostic tests such as biopsies.